TY  - JOUR

T1  - Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.

JO  - Ann Oncol

PY  - 2000/06/01

AU  - Gillespie AM

AU  - Broadhead TJ

AU  - Chan SY

AU  - Owen J

AU  - Farnsworth AP

AU  - Sopwith M

AU  - Coleman RE

ED  - 

DO  - DOI: 10.1023/a:1008349300781

VL  - 11

IS  - 6

SP  - 735

EP  - 741

Y2  - 2025/10/10

ER  -